1. Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15: 565–574.
2. Binder-Foucard Florence, Belot Aurélien, Delafosse Patricia, Remontet Laurent, Woronoff Anne-Sophie, Bossard Nadine (2013) Estimation nationale de l’incidence et de la mortalite par cancer en France entre 1980 et 2012 (Réseau Francim, Service de biostatistique des Hospices civils de Lyon, Institut de veille sanitaire, Institut national du cancer).
3. Cahir C, Guinan E, Dombrowski SU, Sharp L, Bennett K (2015) Identifying the determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I-III breast cancer: a systematic review and meta-analysis. Patient Educ Couns pii: S0738-3991(15)00234-7.
4. Collège de la Haute Autorité de Santé (HAS) (2010) Tumeur maligne, affection maligne du tissu lymphatique ou hématopoïétique cancer du sein (HAS).
5. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VHM, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou M-F, Inbar M, Khaled H, Kielanowska J, Kwan W-H, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381: 805–816.